Category: Dispensaries
-
TGOD vs Wildflower: Underplaying your hand as opposed to overplaying it
Two news releases wafted past me yesterday that caused me to dig deeper than the words written on the page. This sometimes happens out of necessity – a company has to release news about a topic but can’t go into detail yet, or has bad news they don’t particularly want to run a highlighter over.…
-
Xmas news dump: Aphria (APHA.T) subject to ‘unfriendly’ takeover by company CEO advises
This Aphria (APHA.T) story just keeps getting richer, and the unbelievable lack of respect this company is giving the market and regulators is a sight to behold. Let’s recap the last few weeks: So now we’re into the dead days of the 2018 market, just after Christmas and right before New Year, when few are…
-
Tepid Aphria (APHA.T) response to short report accusations sees stock hammered – again
It’s all gone pear-shaped over at Aphria (APHA.T) a day after a short report was filed by Quintessential Capital Management, following up on an earlier short report by Hindenburg Research. In the report, admitted short sellers claimed they’d traveled the globe looking for companies and properties Aphria purchased, sometimes from companies that board members owned…
-
Too professional: Pure Global (PURE.V) and the companies discounted because they’re actually building businesses
Had a conversation on the phone with Stephen Pynn, VP of Corporate Devs at Pure Global (PURE.V) this week that got me thinking. Pure has had an up and down run since landing on the public markets in July of this year. It ebbs and flows like the tides, never getting really beat up, but also…
-
Gamechanger: iAnthus (IAN.C) and MPX Bioceutical (MPX.C) to merge, go after MedMen (MMEN.C)
A week ago, US dispensary roll-up play MedMen (MMEN.C) closed an $86m financing and a $99.95m loan to help them complete a $682m deal to buy PharmaCann, which has ten dispensaries and three weed grows. It was big news and propelled MMEN stock, which many deem to be overpriced before the deal, substantially higher still.…
-
It’s Weed Wednesday: Canadian cannabis is legal, but what does it all mean?
If you thought weed stocks were going to run when the new Canadian cannabis laws came in, guess again. Those had been baked into share price for over a year so, if anything, we at Equity.guru expected today to be the stock price yawner it has so far been. But that’s not always going to…
-
Sold out: Which Canadian cannabis brands are winning on day one?
Recreational cannabis is legal in Canada, praise Jesus. But anyone who thought pre-rolls would be falling from the sky on day one is living in a fantasy world. Queues are long, stores are already running out of hot sellers, and online traffic is proving hot with looky-loos. Assuming you can find a store that is…
-
MedMen (MMEN.C) blows out stock to buy 10 dispensaries, three weed farms in Pharmacann deal
In news that pushed MedMen’s (MMEN.C) share price to new highs, the red shirt crew have announced they’re buying US based Pharmacann LLC for $682 million… or, rather, $682 million of MMEN stock, as of October 9. Mind you, the news drove the company share price up significantly, meaning the actual price now being paid…
-
Organic Wednesday: Rubicon Organics (ROMJ.C) debuts on market as Organigram (OGI.V) finally gets re-certified
If you’re the kind of investor who applies added value to a cannabis company that grows a premium product, that company growing an organic product is likely a big deal to you. And the company being actually certified as organic is likely an even bigger deal. If those two things are true for you, then…
-
MedMen (MMEN.C) legal demands clearer: Half a billion dollars from EquityGuhahahahaha
The Streisand Effect is what happens when a person or company sends out legal threats to stop people from seeing something and, in turn, makes that thing they didn’t want seen go viral. MedMen’s lawyers probably should have talked to their clients about this before they started sending us weird legal demands because wow, you…